Bank of Montreal Can Reduces Stake in STERIS plc $STE

Bank of Montreal Can lowered its stake in STERIS plc (NYSE:STE) by 7.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 71,290 shares of the medical equipment provider’s stock after selling 6,052 shares during the quarter. Bank of Montreal Can owned approximately 0.07% of STERIS worth $17,125,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in STE. Geneos Wealth Management Inc. lifted its holdings in shares of STERIS by 416.0% in the first quarter. Geneos Wealth Management Inc. now owns 129 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 104 shares in the last quarter. Zions Bancorporation National Association UT bought a new stake in STERIS during the 1st quarter worth approximately $37,000. Costello Asset Management INC purchased a new stake in STERIS in the 1st quarter worth approximately $45,000. Atticus Wealth Management LLC bought a new position in STERIS in the 2nd quarter valued at $68,000. Finally, SVB Wealth LLC bought a new position in STERIS in the 1st quarter valued at $69,000. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Analyst Upgrades and Downgrades

STE has been the topic of a number of recent analyst reports. KeyCorp increased their price objective on STERIS from $277.00 to $288.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 22nd. Wall Street Zen upgraded STERIS from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 14th. Morgan Stanley lifted their price target on STERIS from $276.00 to $295.00 and gave the company an “overweight” rating in a research report on Friday, August 8th. Finally, Weiss Ratings restated a “buy (b)” rating on shares of STERIS in a research report on Tuesday, October 14th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $273.50.

Insider Buying and Selling

In other STERIS news, CAO Karen L. Burton sold 7,900 shares of the company’s stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $241.73, for a total transaction of $1,909,667.00. Following the completion of the sale, the chief accounting officer directly owned 5,994 shares in the company, valued at $1,448,929.62. This represents a 56.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CEO Daniel A. Carestio sold 159 shares of the firm’s stock in a transaction dated Monday, October 6th. The shares were sold at an average price of $241.82, for a total value of $38,449.38. Following the transaction, the chief executive officer directly owned 51,096 shares in the company, valued at $12,356,034.72. This trade represents a 0.31% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 18,868 shares of company stock worth $4,585,389 in the last ninety days. 1.07% of the stock is currently owned by insiders.

STERIS Trading Up 1.5%

Shares of STE stock opened at $263.88 on Friday. The business has a 50-day moving average price of $243.98 and a two-hundred day moving average price of $238.89. STERIS plc has a 12-month low of $200.98 and a 12-month high of $265.56. The company has a quick ratio of 1.53, a current ratio of 2.22 and a debt-to-equity ratio of 0.27. The firm has a market cap of $25.99 billion, a P/E ratio of 40.41 and a beta of 1.02.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $2.47 EPS for the quarter, beating the consensus estimate of $2.38 by $0.09. The firm had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. STERIS had a return on equity of 14.17% and a net margin of 11.61%.During the same period in the prior year, the company earned $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. Equities analysts anticipate that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th will be issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date is Tuesday, November 18th. STERIS’s payout ratio is presently 38.59%.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.